uPA/PAI-1在乳腺癌中的表达及其临床意义的研究进展

The clinical significane of the expression of uPA/PAI-1 in breast cancer patients

恶性肿瘤的侵袭及转移需要细胞外基质(extracellular matrix,ECM)的降解,涉及到很多蛋白水解酶类,其中包括尿激酶型纤溶酶原激活物(urokinase-type plasminogen,uPA)系统。uPA系统不仅促进肿瘤的侵袭及转移,还参与癌细胞增殖与肿瘤血管形成。目前,一些研究已证明uPA系统对乳腺癌患者有重要的临床意义,特别是对腋窝淋巴结阴性的患者。本文对uPA/纤溶酶原激活物抑制因子-1(plasminogen inhibitor 1,PAI-1)在乳腺癌中的表达及其临床意义的研究进展作一综述。

Cancer invasion and metastasis required the degradation of extracellular matrix （ECM）, which involved various proteolytic enzymes. One of the most important enzymes systems was the urokinase-type plasminogen activator （uPA） system. The uPA system was not only the promoter of tumor invasion and metastasis, but also associated with cancer cell proliferation and tumor angiogenesis. Recent studies have showed the clinical importance of the uPA system in the breast cancer patients, especially in those with axillary lymph node negative. We reviewed recent studies and researches to get a clearer profile of uPA/plasminogen inhibitor 1 （PAI-1） and provide new strategy to treat breast cancer patients.